ライフサイエンスコーパス: N-acetylmannosamine

1 ype 9V wcjE mediates 6-O-acetylation of beta-N-acetylmannosamine.

2 oup to select for the "boat" conformation of N-acetylmannosamine.

3 cetylglucosamine, N-acetylgalactosamine, and N-acetylmannosamine.

4 hydrolysis of sialic acid into pyruvate and N-acetylmannosamine.

5 able pharmaceuticals N-acetylglucosamine and N-acetylmannosamine.

6 ride repeating unit containing mannoheptose, N-acetylmannosamine, 3-acetamido-3,6-dideoxyglucose, 2-a

7 In vitro the human enzyme uses N-acetylmannosamine 6-phosphate and mannose 6-phosphate

8 gions, and the Neu5Ac catabolic intermediate N-acetylmannosamine-6-phosphate (ManNAc-6P) relieves Nan

9 The essential N-acetylmannosamine-6-phosphate 2-epimerase (NanE) belon

10 The amino sugar epimerase N-acetylmannosamine-6-phosphate 2-epimerase (NanE) has b

11 including an epimerase (NanE) that converts N-acetylmannosamine-6-phosphate to N-acetylglucosamine-6

12 t mechanism to invert the C2 stereocenter of N-acetylmannosamine-6-phosphate.

13 als have evaluated the use of sialic acid or N-acetylmannosamine (a precursor of sialic acid) in pati

14 also contained -CH(2) O-acetylation of beta-N-acetylmannosamine, a modification that disappeared fol

15 sphoramidate chemistry to 1,3,4-O-acetylated N-acetylmannosamine (Ac(3)ManNAc) to deliver ManNAc-6-ph

16 In this work, four different C-3 modified N-acetylmannosamine analogs were tested as potential inh

17 Exogenously supplied N-acetylmannosamine analogues were not converted to LOS-

18 ynthetic pathway by converting UDP-GlcNAc to N-acetylmannosamine are described in this report.

19 tivity of SaNanK along with the ligand-free, N-acetylmannosamine-bound and substrate analog GlcNAc-bo

20 ified EPS is identified as a beta-1,4-linked N-acetylmannosamine chain decorated with terminal alpha-

21 ajority of strains contain homologs of wcgC (N-acetylmannosamine dehydrogenase), wcfF (putative dehyd

22 DP-N-acetylglucosamine 2-epimerase and a UDP-N-acetylmannosamine dehydrogenase, respectively.

23 des, including glucose, glucuronic acid, and N-acetylmannosamine, do not express this activity.

24 e MMP0706 protein used NAD(+) to oxidize UDP-N-acetylmannosamine, forming UDP-N-acetylmannosaminurona

25 (i) the incorporation of labeled leucine and N-acetylmannosamine into immunoprecipitable clusterin in

26 ManDiaz, which is a diazo derivative of N-acetylmannosamine, is found to endure cellular metabol

27 present the crystal structures of the human N-acetylmannosamine kinase (MNK) domain of UDP-N-acetylg

28 N-Acetylmannosamine kinase (NanK) is the second enzyme o

29 omain of UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase in complexes with ManNAc at 1

30 nctional UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase that transforms UDP-N-acetylg

31 Binding kinetics of the inhibitor and human N-acetylmannosamine kinase were evaluated using surface

32 ies, UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase, in sialic acid biosynthetic

33 Using UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase-deficient cells, we confirm t

34 iosynthesis, N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase.

35 osynthetic pathway with exogenously supplied N-acetylmannosamine (ManNAc) analogs has many potential

36 The high affinity ligand N-acetylmannosamine (ManNAc) binds in the S1 site, predo

37 gh the metabolic transformation of unnatural N-acetylmannosamine (ManNAc) derivatives.

38 phosphate synthase (SAS) in combination with N-acetylmannosamine (ManNAc) feeding has been shown to o

39 e that transforms UDP-N-acetylglucosamine to N-acetylmannosamine (ManNAc) followed by its phosphoryla

40 oducts were readily advanced to a variety of N-acetylmannosamine (ManNAc) frameworks, using an intram

41 N-Acetylmannosamine (ManNAc) is the first committed inte

42 ne diphospho-N-acetylglucosamine 2-epimerase/N-acetylmannosamine (ManNAc) kinase (GNE/MNK), result in

43 Administration of the sialic acid precursor N-acetylmannosamine (ManNAc) led to improved sialylation

44 onstoichiometrically acetylated at O3 of the N-acetylmannosamine (ManNAc) residue.

45 btilis is catalyzed by TagA, which transfers N-acetylmannosamine (ManNAc) to the C4 hydroxyl of a mem

46 step in this process, the production of free N-acetylmannosamine (ManNAc), has not been defined.

47 yl sugar monomers, based on fucose (Fuc) and N-acetylmannosamine (ManNAc), were incorporated into fuc

48 erase (NmSiaD(W)) identified 4-azido-4-deoxy-N-acetylmannosamine (ManNAc4N(3)) and 6-azido-6-deoxy-N-

49 annosamine (ManNAc4N(3)) and 6-azido-6-deoxy-N-acetylmannosamine (ManNAc6N(3)) as suitable chemoenzym

50 Starting from N-acetylmannosamine, mannose or their chemically or enzy

51 ity to synthesize the sialic acid precursor, N-acetylmannosamine (neuC), indicated that NeuO does not

52 3 phenotype was rescued by exogenously added N-acetylmannosamine or mannosamine but not by the same c

53 Oral administration of N-acetylmannosamine rescues skeletal myopathy, as well a

54 a sialyl transferase (cstII) and a putative N-acetylmannosamine synthetase (neuC1), part of the bios

55 f tailored enzyme fourfold, and can increase N-acetylmannosamine titer by 75.0%.

56 -GlcNAc) precursor that is epimerized to UDP-N-acetylmannosamine (UDP-ManNAc) and then oxidized to UD

57 UDP-N-acetyl glucosamine (UDP-GlcNAc) to UDP-N-acetylmannosamine (UDP-ManNAc).

58 nd degradation pathway and adds phosphate to N-acetylmannosamine using ATP to prime the molecule for

59 The HPLC profile of alkali-treated N-acetylmannosamine was identical to that of the product

60 om the natural condensation of pyruvate with N-acetylmannosamine, yielding N-acetylneuraminic acid, t